Proteocyte Diagnostics announces support from the Government of Canada to accelerate product development

Toronto, ON; December 16, 2014 – Proteocyte Diagnostics Inc., a company with a novel test for early identification of oral cancers, today announced that it will receive financial support and technological advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP).

Proteocyte Diagnostics is a Canadian molecular diagnostics company that has developed a novel diagnostics test, Straticyte™ that objectively and accurately detects precancerous oral lesions at high risk of becoming cancerous. Straticyte is the first and only molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score as evidenced by retrospective clinical studies.

NRC-IRAP’s support will enable Proteocyte Diagnostics to accelerate the automation of the Straticyte test and refine the prediction algorithm for even greater accuracy. The research outcomes will enable Proteocyte Diagnostics to handle increased test volumes from a larger geographical market while ensuring greater accuracy for oral pathologists and oral maxillofacial surgeons.

“We appreciate the support of NRC-IRAP,” said Dr. Mario Thomas, President of Proteocyte Diagnostics. “This allows us to add to our product development team and move the Straticyte test forward. Our innovative diagnostics test is that much closer to being available for patients.”

About Proteocyte
Proteocyte Diagnostics Inc. is a Canadian molecular diagnostics company that develops and commercializes a novel diagnostics technology, Straticyte™ that offers objective and accurate early diagnosis of precancers and cancers. The company’s first product objectively and accurately distinguishes between those precancerous oral lesions at high risk of becoming cancerous and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Proteocyte management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.